Novo Nordisk A/S (NOV) Stock Price & News

Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily obesity and diabetes medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s. Novo employs approximately 69,500 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares. Novo is a full member of the European Federation of Pharmaceutical Industries and Associations. The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia

About Novo Nordisk A/S

CEOMike Doustdar

Employees66.7K

Founded1923

HeadquartersBagsværd, Capital Region of Denmark, Denmark

SectorHealth Care

IndustryPharmaceutical industry

Websitenovonordisk.com

Last report

Nov 4, 2026

Fiscal period

Q3 2026

DKK 5.79 / DKK 4.92

+17.78%beat

Revenue / Est. (DKK)

79.20B / 73.40B

+7.89%beat

Fiscal Q3 2026 earnings call

Waiting for the earnings call

At a glance

Insights from the latest news and reports

Previous reportsAll values in DKK

Loading Previous Earnings...

All values in DKK	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Revenue	79.14B	96.82B	78.49B	79.20B
Cost of goods sold	14.17B	13.60B	17.10B	14.18B
Cost of revenue	14.17B	13.60B	17.10B	14.18B
Research and development expenses	12.67B	10.28B	11.46B	15.26B
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	17.14B	13.22B	16.31B	16.26B
Operating expense	29.73B	23.61B	28.00B	33.30B
Total operating expenses	43.90B	37.20B	45.10B	47.48B
Operating income	35.24B	59.62B	33.39B	31.72B
Other non operating income	-241.00M	-	-	-443.00M
EBT including unusual items	34.18B	62.17B	26.88B	21.43B
EBT excluding unusual items	37.62B	62.17B	33.20B	30.14B
Income tax expense	7.29B	13.62B	5.89B	4.69B
Effective tax rate	21.34%	21.90%	21.90%	21.90%
Other operating expenses	-81.00M	106.00M	234.00M	1.79B
Net income	26.89B	48.56B	20.99B	16.74B
Net profit margin	33.98%	50.15%	26.74%	21.14%
Earnings per share	6.04	6.63	6.18	5.79
Interest and investment income	4.41B	-	1.31B	-
Interest expense	-4.97B	-	-1.50B	-1.13B
Net interest expenses	-560.00M	-	-186.00M	-1.13B
Depreciation and amortization charges	-	-	-	-
EBITDA	36.66B	63.13B	36.99B	35.32B
Gain or loss from assets sale	-	-	-	-

Ask anything